News

ERDF funds enable the incorporation of CMRB to IDIBELL’s facilities

The Spanish Ministry of Economy and Competitiveness (MINECO) has granted a project to Bellvitge Biomedical Research Institute (IDIBELL) for the optimization, adaptation, improvement of facilities and acquisition of technological equipment at IDIBELL because of the forthcoming integration of the Center for Regenerative Medicine in Barcelona (CMRB) in these spaces. The project, which is funded by […]

Leer más about ERDF funds enable the incorporation of CMRB to IDIBELL’s facilities

ICFO and IDIBELL, together into new projects

joint conference ICFO-IDIBELL Detecting , Predicting and Fighting Resistance to antiangiogenic Therapies Non-invasive Monitoring of Local Hemodynamics to Characterize Suspicious Masses and to Predict Therapy Outcomes Applications to Biomedicine of Light and Nanotechnology Superresolution Techniques to Study Polarized Trafficking of Signaling Proteins in Photoreceptor Cells of the Retina Advanced Microscopy Techniques: Biomedical Imaging Applications at Nano, Micro and Macro Levels.

Leer más about ICFO and IDIBELL, together into new projects

IDIBELL, worthy cause of the 7th Cursa Nocturna Sport form L’Hospitalet

Cursa Nocturna Sport of L’Hospitalet From this edition, solidarity donations from runners will go to projects led by biomedical researchers from IDIBELL. PREDICOP 2,108 catalan women

Leer más about IDIBELL, worthy cause of the 7th Cursa Nocturna Sport form L’Hospitalet

Identify a biochemical alteration responsible for the resistance of the most aggressive brain tumors

Researchers at the Institute of Neurosciences, UAB (INC) have identified the biochemical and molecular alterations leading to resistance to radiotherapy and chemotherapy in glioblastoma, the most aggressive brain tumor. The finding could allow, in the future, to design new, more effective therapies. Original article:

Leer más about Identify a biochemical alteration responsible for the resistance of the most aggressive brain tumors

Xavier Bosch, IDIBELL Ombudsman

On October 14th, 2015, Dr. Francesc Xavier Bosch was presented and sanctioned by the Internal IDIBELL Scientific Committee as the Ombudsman of the institution. Dr. Bosch, Doctor of Medicine from the Autonomous University of Barcelona, has been responsible for the Cancer Epidemiology Research Program of the Catalan Institute of Oncology (ICO), head of the Infection […]

Leer más about Xavier Bosch, IDIBELL Ombudsman

A new therapeutic strategy for more aggressive lung tumor

Lung cancer is one of the most prevalent, with more than 20,000 new cases diagnosed each year in Spain. In 30% intervenes KRAS oncogene, which causes more aggressive tumor. It is also a type of lung cancer that does not has targeted therapies beyond the standard cisplatin. A study led by researchers Mariano Barbacid and […]

Leer más about A new therapeutic strategy for more aggressive lung tumor

Eva Gonzalez Suarez gets Consolidator Grant from the European Research Council

The head of the group of Transformation and Metastasis PEBC-IDIBELL, Eva Gonzalez Suarez has received an ERC Consolidator Grant from the European Research Council (ERC) to develop its PLEIO-RANK project to develop a single therapy capable of reducing metastasis and mortality in solid tumors. The grant supposes a funding 2 million Euros for the next five years.

Leer más about Eva Gonzalez Suarez gets Consolidator Grant from the European Research Council

Researcher Oriol Casanovas received a Proof of Concept 2015 grant awarded by the European Union

The European Research Council (ERC) has announced the names of the scientists who will receive the Proof of Concept (PoC) 2015 grant, which is only accessible to scientists who already have a grant from the ERC. Oriol Casanovas, leader of the Tumor Angiogenesis group of the PROCURE program from ICO and IDIBELL has been one […]

Leer más about Researcher Oriol Casanovas received a Proof of Concept 2015 grant awarded by the European Union
Scroll to Top